肝癌在免疫细胞 DNA 甲基化中的特征。

The signature of liver cancer in immune cells DNA methylation.

机构信息

1Beijing Youan Hospital, Capital Medical School, Beijing, China.

2Department of Pharmacology and Therapeutics, McGill University, 3655 Sir William Osler Promenade, Montreal, Quebec H3G 1Y6 Canada.

出版信息

Clin Epigenetics. 2018 Jan 18;10:8. doi: 10.1186/s13148-017-0436-1. eCollection 2018.

BACKGROUND

The idea that changes to the host immune system are critical for cancer progression was proposed a century ago and recently regained experimental support.

RESULTS

Herein, the hypothesis that hepatocellular carcinoma (HCC) leaves a molecular signature in the host peripheral immune system was tested by profiling DNA methylation in peripheral blood mononuclear cells (PBMC) and T cells from a discovery cohort ( = 69) of healthy controls, chronic hepatitis, and HCC using Illumina 450K platform and was validated in two validation sets ( = 80 and = 48) using pyrosequencing.

CONCLUSIONS

The study reveals a broad signature of hepatocellular carcinoma in PBMC and T cells DNA methylation which discriminates early HCC stage from chronic hepatitis B and C and healthy controls, intensifies with progression of HCC, and is highly enriched in immune function-related genes such as , a current cancer immunotherapy target. These data also support the feasibility of using these profiles for early detection of HCC.

背景

一个世纪前，人们提出了宿主免疫系统的改变对癌症进展至关重要的观点，最近这一观点得到了实验支持。

结果

本研究通过 Illumina 450K 平台对来自发现队列（健康对照组 = 69 例、慢性乙型肝炎患者 = 69 例和 HCC 患者 = 69 例）的外周血单个核细胞（PBMC）和 T 细胞进行 DNA 甲基化分析，检测肝癌（HCC）是否在宿主外周免疫系统中留下分子特征，并在两个验证队列（验证队列 1 = 80 例、验证队列 2 = 48 例）中使用焦磷酸测序进行验证。